Lancet tags COVAXIN as safe vaccine with no severe side-effects
New Delhi : UK's medical journal 'The Lancet' has tagged COVAXIN as a safe vaccine against coronavirus with no major signs of side-effects. It mentioned that the vaccine has performed much better in the Phase 2 trials as compared to Phase 1.
According to the report released on Tuesday, the vaccine developed by Hyderabad-based Bharat Biotech showed better reactogenicity and safety outcomes, and enhanced humoral and cell-mediated immune responses compared with the Phase 1 trials.
It comes just days after Bharat Biotech and Indian Council of Medical Research (ICMR) announced that Covaxin demonstrated nearly 81% efficacy in interim Phase 3 trials.
The paper claimed that the most adverse effect registered in the second phase of vaccination was pain at the injection site, followed by headache, fever and fatigue.
"No severe or life-threatening solicited adverse events were reported. No significant differences in safety were observed between the two groups," it said.